ReviewRespiratory research2018
Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question?
Review in Respiratory research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 199 citations in OpenAlex.
- Nebulized Budesonide Prevents Airway Inflammation in Children with High Total IgE Levels After Open Heart Surgery with Cardiopulmonary Bypass: A Prospective Randomized Controlled Trial.Pediatric cardiology · 2025Trial
- Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.Advances in therapy · 2020Trial
- AhR as a Common Denominator in Immunity and Inflammation in Chronic Lung Diseases: Molecular and Clinical Insights.Diseases (Basel, Switzerland) · 2026Review
- Control first, tolerance second: biologics as enablers of allergen immunotherapy in severe allergic asthma.Frontiers in allergy · 2026Review
- Central compartment atopic disease: Advances in pathogenesis and stratified treatment.The Journal of international medical research · 2026Review
- Evaluation of Total Serum IgE Level and Associated Factors in Asthmatic Patients at the University of Gondar Hospital, Northwest Ethiopia: A Comparative Cross-Sectional Study.Health science reports · 2026Article
- β-arrestin2: an emerging player and potential therapeutic target in inflammatory immune diseases.Acta pharmacologica Sinica · 2025Review
- Article
- Unraveling the role of shrimp hydrolysate as a food supplement in the immune function and fecal microbiota of beagle dogs.Scientific reports · 2025Article
- Metabolomics in Childhood Asthma - a Promising Tool to Meet Various Clinical Needs.Current allergy and asthma reports · 2025Review
- Review
- Blockade of cysteinyl leukotriene receptor 1 alleviates asthma by inhibiting bronchial epithelial cell apoptosis and activating the Nrf2 signaling pathway.Experimental and therapeutic medicine · 2025Article
- [Contribution to the establishment of reference ranges for total immunoglobulin E: a cross-sectional study among blood donors in Abidjan (Ivory Coast)].The Pan African medical journal · 2025Article
- Hydrogen Gas Inhalation Alleviates Airway Inflammation and Oxidative Stress on Ovalbumin-Induced Asthmatic BALB/c Mouse Model.Antioxidants (Basel, Switzerland) · 2024Article
- IgG Antibody Titers AgainstTropical medicine and infectious disease · 2024Article
- Article
- A Review on Asthma and Allergy: Current Understanding on Molecular Perspectives.Journal of clinical medicine · 2024Review
- Application of nano- and micro-particle-based approaches for selected bronchodilators in management of asthma.3 Biotech · 2024Review
- Progesterone modulates the immune microenvironment to suppress ovalbumin-induced airway inflammation by inhibiting NETosis.Scientific reports · 2024Article
- Association between specific IgE to staphylococcal enterotoxin B and the eosinophilic phenotype of asthma.The Korean journal of internal medicine · 2024Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchial asthma (BA) is a chronic inflammatory disease with a marked heterogeneity in pathophysiology and etiology. The heterogeneity of BA may be related to the inducing mechanism(s) (allergic vs non-allergic), the histopathological background (eosinophilic vs non-eosinophilic), and the clinical manifestations, particularly in terms of severity and frequency of exacerbations. Asthma can be divided into at least two different endotypes based on the degree of Th2 inflammation (T2 'high' and T2 'low'). For patients with severe uncontrolled asthma, monoclonal antibodies (mAbs) against immunoglobulin E (IgE) or interleukin (IL)-5 are now available as add-on treatments. Treatment decisions for individual patients should consider the biological background in terms of the "driving mechanisms" of inflammation as this should predict the patients' likely responses to treatment. The question is not whether an anti-IgE or an anti-eosinophilic strategy is more effective, but rather what the mechanism is at the origin of the airway. While IgE is involved early in the inflammatory cascade and can be considered as a cause of allergic asthma, eosinophilia can be considered a consequence of the whole process. This article discusses the different roles of the IgE and IL-5/eosinophil pathways in the pathogenic mechanisms of airway inflammation occurring in allergic asthma, and the possible reasons to choose an anti-IgE mAb or anti-IL-5 treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.